Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Samer El-Bawab"'
Autor:
Marcus Baaz, Tim Cardilin, Floriane Lignet, Astrid Zimmermann, Samer El Bawab, Johan Gabrielsson, Mats Jirstrand
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-19 (2023)
Abstract Background To increase the chances of finding efficacious anticancer drugs, improve development times and reduce costs, it is of interest to rank test compounds based on their potential for human use as early as possible in the drug developm
Externí odkaz:
https://doaj.org/article/a6f9721279f44bcf9f33ddd27b842889
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 5, Pp 594-603 (2022)
Abstract Pan‐proteasome inhibitors (pPIs) significantly improve outcomes in patients with multiple myeloma; however, their indiscriminate inhibition of multiple proteasome and immunoproteasome subunits causes diverse toxicities, including thrombocy
Externí odkaz:
https://doaj.org/article/037f8e2d220e446cbde8d82c7134ae1e
Autor:
Wenyuan Xiong, Manja Friese‐Hamim, Andreas Johne, Christopher Stroh, Manfred Klevesath, Gerald S. Falchook, David S. Hong, Pascal Girard, Samer El Bawab
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 5, Pp 428-440 (2021)
Abstract Tepotinib is a highly selective and potent MET inhibitor in development for the treatment of patients with solid tumors. Given the favorable tolerability and safety profiles up to the maximum tested dose in the first‐in‐human (FIH) trial
Externí odkaz:
https://doaj.org/article/336092d3d9d74e2798fde9141c4ad366
Autor:
David S. Hong, Samer El Bawab, Pascal Girard, Manja Friese-Hamim, Friedhelm Bladt, Andreas Johne, Uz Stammberger, Rolf Bruns, Manfred Klevesath, Daniel V. Catenacci, Ghazaleh Eskandari, Filip Janku, Sarina A. Piha-Paul, Siqing Fu, Wenyuan Xiong, Hesham M. Amin, Razelle Kurzrock, Gerald S. Falchook
Purpose:Tepotinib is an oral, potent, highly selective MET inhibitor. This first-in-man phase I trial investigated the MTD of tepotinib to determine the recommended phase II dose (RP2D).Patients and Methods:Patients received tepotinib orally accordin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::671f44bbd9f87afda836e289bffa0f98
https://doi.org/10.1158/1078-0432.c.6529907
https://doi.org/10.1158/1078-0432.c.6529907
Autor:
David S. Hong, Samer El Bawab, Pascal Girard, Manja Friese-Hamim, Friedhelm Bladt, Andreas Johne, Uz Stammberger, Rolf Bruns, Manfred Klevesath, Daniel V. Catenacci, Ghazaleh Eskandari, Filip Janku, Sarina A. Piha-Paul, Siqing Fu, Wenyuan Xiong, Hesham M. Amin, Razelle Kurzrock, Gerald S. Falchook
Supplementary information showing details of study criteria, bioasssays, preclinical modelling, PK data, safety and efficacy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7690cb145a7b5a77f8a21817acc152e7
https://doi.org/10.1158/1078-0432.22478273
https://doi.org/10.1158/1078-0432.22478273
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 11:594-603
Pan-proteasome inhibitors (pPIs) significantly improve outcomes in patients with multiple myeloma; however, their indiscriminate inhibition of multiple proteasome and immunoproteasome subunits causes diverse toxicities, including thrombocytopenia. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::737e69991fcbb7976f128d0ceb596c71
https://doi.org/10.1002/psp4.12743
https://doi.org/10.1002/psp4.12743
Autor:
Tim Cardilin, Astrid Zimmermann, Samer El Bawab, Joachim Almquist, Floriane Lignet, Mats Jirstrand, Johan Gabrielsson
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 49:167-178
A central question in drug discovery is how to select drug candidates from a large number of available compounds. This analysis presents a model-based approach for comparing and ranking combinations of radiation and radiosensitizers. The approach is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcace8ace2394ec331e3a5295233c1f4
https://doi.org/10.1007/s10928-021-09784-7
https://doi.org/10.1007/s10928-021-09784-7
Autor:
Floriane Lignet, Christina Esdar, Gina Walter-Bausch, Manja Friese-Hamim, Sofia Stinchi, Elise Drouin, Samer El Bawab, Andreas D. Becker, Claude Gimmi, Michael P. Sanderson, Felix Rohdich
Publikováno v:
The Journal of pharmacology and experimental therapeutics.
M3258 is an orally bioavailable, potent, selective, reversible inhibitor of the large multifunctional peptidase 7 (LMP7, β5i, PSMB8) proteolytic subunit of the immunoproteasome; a component of the cellular protein degradation machinery, highly expre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb0b32417eb18d77d30e0666a98cc907
https://pubmed.ncbi.nlm.nih.gov/36273822
https://pubmed.ncbi.nlm.nih.gov/36273822
Autor:
Paul A Clarke, Maria-Jesus Ortiz-Ruiz, Robert TePoele, Olajumoke Adeniji-Popoola, Gary Box, Will Court, Stephanie Czasch, Samer El Bawab, Christina Esdar, Ken Ewan, Sharon Gowan, Alexis De Haven Brandon, Phillip Hewitt, Stephen M Hobbs, Wolfgang Kaufmann, Aurélie Mallinger, Florence Raynaud, Toby Roe, Felix Rohdich, Kai Schiemann, Stephanie Simon, Richard Schneider, Melanie Valenti, Stefan Weigt, Julian Blagg, Andree Blaukat, Trevor C Dale, Suzanne A Eccles, Stefan Hecht, Klaus Urbahns, Paul Workman, Dirk Wienke
Publikováno v:
eLife, Vol 5 (2016)
Mediator-associated kinases CDK8/19 are context-dependent drivers or suppressors of tumorigenesis. Their inhibition is predicted to have pleiotropic effects, but it is unclear whether this will impact on the clinical utility of CDK8/19 inhibitors. We
Externí odkaz:
https://doaj.org/article/a201fbf6b4ca430996a70dd003f4f498
Autor:
Christopher Stroh, Gerald Steven Falchook, Andreas Johne, Samer El Bawab, Manja Friese-Hamim, Pascal Girard, Manfred B. Klevesath, David S. Hong, Wenyuan Xiong
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 5, Pp 428-440 (2021)
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 5, Pp 428-440 (2021)
Tepotinib is a highly selective and potent MET inhibitor in development for the treatment of patients with solid tumors. Given the favorable tolerability and safety profiles up to the maximum tested dose in the first‐in‐human (FIH) trial, an effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe83c280eee2878795a0fff47f6768f1
https://doi.org/10.1002/psp4.12602
https://doi.org/10.1002/psp4.12602